jRCT2031240338招募中不适用
Ezharmia Tablet Post-marketing Surveillance (relapsed or refractory peripheral T-cell lymphoma)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 150
- 主要终点
- Cumulative incidence of AEs
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- No limit 至 No limit（—）
- 性别
- All
入选标准
- •All patients who start receiving Ezharmia Tablet during the registration period.
排除标准
- 未提供
结局指标
主要结局
Cumulative incidence of AEs
safety specifications : myelosuppression, infection and the secondary malignancy of the survey
次要结局
未报告次要终点
研究者
相似试验
招募中
Unknown
Ezharmia Tablet Post-marketing SurveillanceRelapsed or refractory Adult T-cell leukemia/lymphoma (ATL)JPRN-jRCT2031220503Matsuoka Yomei150
招募中
Unknown
VANFLYTA Tablet Post-marketing Surveillance StudyRelapsed or refractory acute myeloid leukemia with FLT3-ITD mutation positiveJPRN-jRCT1080224910DAIICHI SANKYO CO., LTD.210
已完成
4 期
Prescriber Based, Active Post Marketing Surveillance Study (PMS) to Generate The Safety & Efficacy Data Of Diazepam and Propranolol in The Treatment of Chronic Anxiety & Insomnia in Actual Field Conditions Of Use.CTRI/2020/03/023789AN Pharmacia Laboratories Pvt ltd200
已完成
4 期
Treatment of chronic anxietyCTRI/2020/03/023823A N Pharmacia Laboratories Pvt Ltd200
招募中
4 期
Post Marketing Surveillance Study (PMS) to generate safety and efficacy data of Febrex Plus SyrupCTRI/2020/06/025925Indoco Remedies Limited